
    
      By enrolling patients with nasopharyngeal carcinoma adapted to enrolled criteria, this study
      will document for the first time the safety and the short and long term efficacy of
      HepaSphere interventional therapy using digital subtraction angiography （DSA） for
      nasopharyngeal carcinoma.
    
  